食管癌放疗增敏剂的临床研究

doi:10.3760/cma.j.issn.1673-422X.2015.12.013

摘要/Abstract

摘要： 放疗增敏剂作为一种新型抗肿瘤药物与放疗具有协同作用，能提高放射线对肿瘤细胞的杀伤率，增强放疗疗效。近年来由于新理论新技术的提出，放疗增敏剂的研究范围延伸至不同领域，取得了飞跃的发展，从传统的DNA靶点增敏剂到如今包括纳米微粒在内的新型放疗增敏剂。因此，放疗增敏剂联合放疗将作为一种新的食管癌治疗策略应用于临床，提高食管癌的治疗效果。

关键词: 食管肿瘤, 放射疗法, 辐射增敏药

Abstract: Radiosensitizer as a promising novel antitumor medicine has synergetic effects with radiotherapy, and can enhance the kill rate of tumor cells and radiotherapy effect. In recent years, due to the new theory and technology, the researches of radiosensitizer extend to different fields, from the traditional DNA target sensitizer to new radiosensitizer including nanoparticles. Consequently, radiosensitizer combined with radiotherapy will become a new and effective treatment strategy for esophageal carcinoma to enhance the therapeutic effect of esophageal carcinoma.

Key words: Esophageal neoplasms, Radiotherapy, Radiation-sensitizing agents

康梅,权循凤. 食管癌放疗增敏剂的临床研究[J]. 国际肿瘤学杂志, 2015, 42(12): 932-935.

Kang Mei, Quan Xunfeng. Clinical study on the radiosensitizer of esophageal carcinoma[J]. Journal of International Oncology, 2015, 42(12): 932-935.

参考文献

［1］ Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics［J］. CA Cancer J Clin, 2012, 62(4): 220-241. ［2］ Siegel R, Naishadham D, Jemal A, et al. Cancer statistics, 2013［J］. CA Cancer J Clin, 2013, 63(1): 11-30. ［3］ Ma DY, Tan BX, Liu M, et al. Concurrent threedimensional conformal radiotherapy and chemotherapy for postoperative recurrence of mediastinal lymph node metastases in patients with esophageal squamous cell carcinoma: a phase 2 singleinstitution study［J］. Radiat Oncol， 2014, 9: 28. ［4］刘宗展. 奈达铂增敏放疗与单纯放疗治疗50例食管癌的疗效对比分析［J］. 中国医药指南, 2013, 5(15): 34-36. ［5］ Kim YJ, Lee WJ, Woo SM, et al． Comparison of capecitabine and 5fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer［J］. Radiat Oncol, 2013, 8(8): 160-163. ［6］ Uehara K, Hiramatsu K, Maeda A, et al. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poorrisk rectal cancer: NSOG 03 phase Ⅱ trial［J］． Jpn J Clin Oncol, 2013， 43(10): 964-971. ［7］ Shen ZH, Wu XH, Li B, et al. Nedaplatin concurrent with threedimensional conformal radiotherapy for treatment of locally advanced esophageal carcinoma［J］. World J Gastroenterol, 2013, 19(48): 9447-9952. ［8］ Zeng YC, Wu R, Xu ZG, et al． Safety and radiationenhancing effect of sodium glycididazole in locoregionally advanced laryngeal cancers previously treated with platinumcontaining chemotherapy regimens:a preliminary report［J］. Cancer Radiother, 2010, 14(1): 59-64. ［9］王明智, 吴伟, 吴刚, 等. 甘氨双唑钠对食管癌放疗增敏作用的临床观察［J］. 中国现代医药杂志, 2011, 13（10）: 63-65. ［10］秦尚斌, 王雅棣, 杨俊泉, 等. 甘氨双唑钠胸段食管鳞癌放射增敏作用——Ⅲ期多中心随机对照研究［J］. 中华放射肿瘤学杂志, 2012,13(10): 426-429．［11］米登海, 任维维, 田金徽, 等. 甘氨双唑钠对食管癌放射治疗增敏作用的Meta分析［J］. 中国循证医学杂志, 2012, 12(9): 1122-1128. ［12］ Cui C, Mao L, Chi Z, et al. A phase Ⅱ, randomized doubleblind,placebocontrolled multicenter trial of endostar in patients with metastic melanoma［J］. Mol Ther, 2013, 21(7): 1456-1463. ［13］ Jiang XD, Dai P, Wu J, et al. Effect of recombinant human endostatin on radiosensitivity in patients with nonsmallcell lung cancer［J］. Int J Radiation Oncol Biol Phys, 2012, 83(4): 1272-1277. ［14］ McGee MC, Hamner JB, Williams RF, et al. Impmved intmtumoral oxygenaltion through vascular normalizetion increase glioma sensitivity to ionizing radiation［J］. Int J Radiat Oncol Biol Phys, 2010, 76(5): 1537-1545. ［15］胜世杰, 孙静, 冯连杰. 恩度联合三维适形放疗治疗老年晚期食管癌临床观察［J］．肿瘤基础与临床, 2010, 23(2): 149-150．［16］王春英, 程明. 尼妥珠单抗联合三维适形放疗治疗根治性放疗后复发食管癌的疗效分析［J］. 中国药物与临床, 2013, 13(4): 504-505. ［17］ Ruhstaller T, Hess M, Dietrich D. et a1. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable,locally advanced esophageal carcinoma:a prospective．multicenter phase ⅠB/Ⅱ Trial(SAKK 75/06)［J］. J Clin Oncol, 201l, 29(6): 626-631. ［18］ Amato E, Italiano A, Leotta S, et al. Monte Carlo study of the dose enhuancement effect of gold nanoparticles duringn Xray therapies and evaluation and evaluation of the antiangiogenic effect on tumour capillary vessels［J］. J Xray Sci Technol, 2013, 21(2): 237-247. ［19］ Hainfeld JF， Dilmanian FA, Zhong Z, et al. Gold nanopartiecles enhance the radiation therapy of a murine squamous cell carcinoma［J］. Phys Med Biol, 2010, 55(11): 3045-3059. ［20］ Jeremic B, Aguerri AR, Filipovic N. Radiosensitization by gold nanoparticles［J］. Clin Transl Oncol, 2013, 15(8): 593-601. ［21］ Qiao Q, Jiang Y, Li G. Curcumin improves the antitumor effect of Xray irradiation by blocking the NKkappaB pathway:an invitro study of lymphoma［J］. Anticancer Drugs, 2012, 23(6): 597-605. ［22］吴宏, 闫国成, 王双全, 等. 姜黄素对胃癌细胞放疗增敏作用的研究［J］. 陕西医学杂志, 2014, 43(2): 137-139. ［23］ Chiu HW, Lin JH, Chen YA, et al. Combination treatment with arsenic trioxide and irradiation enhances cellkilling effects in human fibrosarcoma cells in vitro and through induction of both autophagy and apoptosis［J］． Autophagy, 2010, 6(3): 353-365. ［24］景绍武, 王雅棣, 吴凤鹏, 等. 三氧化二砷对食管癌细胞株Eca109的放射增敏作用及机制［J］. 肿瘤防治研究, 2011, 38(6): 620-623. ［25］ Blattmann C, Thiemann M, Stenzinger A, et al. Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model［J］. Strahlenther Onkol, 2013, 189(11): 957-966. ［26］ Chen X, Wong P, Radany E, et al. HDAC inhibitor, valproic acid,induces p53dependent radiosensitization of colon cancer cells［J］. Cancer Biother Radiopharm, 2009, 24(6): 689-699. ［27］ Dong M, Ning ZQ, Xing PY, et al. Phase Ⅰ study of chidamide(CS055/HBI8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas［J］. Cancer Chemother Pharmacol, 2012, 69(6): 1413-1422. ［28］葛宜枝, 汪步海, 徐立春. 肿瘤坏死因子α的放疗增敏机制［J］. 国际肿瘤学杂志, 2015, 42(1): 49-51. ［29］ Dumont FJ, Bischoff P. Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapy［J］. Curr Cancer Drug Targets, 2012, 12(8): 899-924.

[1]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[4]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[5]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[6]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[7]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[8]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[9]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[10]	山东省医学会肺癌食管癌多学科联合委员会. 山东省医学会食管癌多学科规范化诊疗指南（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(7): 385-397.
[11]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[12]	许萌, 姜伟, 朱海涛, 曹雄锋. 癌相关成纤维细胞在肿瘤放疗抵抗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 227-230.
[13]	石小琪, 汪红艳. 肠道菌群与放射性肠炎的相互作用及研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 244-247.
[14]	冀世玉, 张明鑫, 谢华红, 白渊, 王彤. 不同支架治疗晚期食管癌患者的疗效观察[J]. 国际肿瘤学杂志, 2023, 50(2): 76-81.
[15]	巩合义, 伊艳, 张健, 李宝生. 局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略[J]. 国际肿瘤学杂志, 2023, 50(12): 745-750.